Aptamers Versus Vascular Endothelial Growth Factor (VEGF): A New Battle against Ovarian Cancer

Abstract

Cancer is one of the diseases that causes a high mortality as it involves unregulated and abnormal cell growth proliferation that can manifest in any body region. One of the typical ovarian cancer symptoms is damage to the female reproductive system. The death rate can be reduced through early detection of the ovarian cancer. Promising probes that can detect ovarian cancer are suitable aptamers. Aptamers, i.e., so-called chemical antibodies, have a strong affinity for the target biomarker and can typically be identified starting from a random library of oligonucleotides. Compared with other probes, ovarian cancer targeting using aptamers has demonstrated superior detection effectiveness. Various aptamers have been selected to detect the ovarian tumor biomarker, vascular endothelial growth factor (VEGF). The present review highlights the development of particular aptamers that target VEGF and detect ovarian cancer at its earliest stages. The therapeutic efficacy of aptamers in ovarian cancer treatment is also discussed.

Biomimetic functionalized metal organic frameworks as multifunctional agents: Paving the way for cancer vaccine advances

“…The researchers also showed that the PEI-Fn-MOF has the ability to target immune cells known as dendritic cells, which are essential for the process of beginning an immune response to cancer cells. Another research discusses the potential of aptamers in the development of vaccines and Metal-Organic Frameworks (MOFs) for ovarian cancer treatment [ 122 ]. It likely explores how aptamers can be used to elicit an immune response against ovarian cancer cells by targeting VEGF.…”